AU2004273779B2 - Compositions for inactivating pathogenic microorganisms, methods of making the compositions, and methods of use thereof - Google Patents

Compositions for inactivating pathogenic microorganisms, methods of making the compositions, and methods of use thereof Download PDF

Info

Publication number
AU2004273779B2
AU2004273779B2 AU2004273779A AU2004273779A AU2004273779B2 AU 2004273779 B2 AU2004273779 B2 AU 2004273779B2 AU 2004273779 A AU2004273779 A AU 2004273779A AU 2004273779 A AU2004273779 A AU 2004273779A AU 2004273779 B2 AU2004273779 B2 AU 2004273779B2
Authority
AU
Australia
Prior art keywords
nanoemulsion
composition
oil
microorganism
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2004273779A
Other languages
English (en)
Other versions
AU2004273779A1 (en
AU2004273779A2 (en
Inventor
Ted C. Annis
James R. Baker
Tarek Hamouda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanobio Corp
Original Assignee
Nanobio Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanobio Corp filed Critical Nanobio Corp
Publication of AU2004273779A1 publication Critical patent/AU2004273779A1/en
Publication of AU2004273779A2 publication Critical patent/AU2004273779A2/en
Application granted granted Critical
Publication of AU2004273779B2 publication Critical patent/AU2004273779B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
AU2004273779A 2003-06-04 2004-06-03 Compositions for inactivating pathogenic microorganisms, methods of making the compositions, and methods of use thereof Active AU2004273779B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45763303P 2003-06-04 2003-06-04
US60/475,633 2003-06-04
PCT/US2004/017417 WO2005027872A2 (fr) 2003-06-04 2004-06-03 Compositions pour l'inactivation de micro-organismes pathogenes, procedes de fabrication de compositions, et leurs procedes d'utilisation

Publications (3)

Publication Number Publication Date
AU2004273779A1 AU2004273779A1 (en) 2005-03-31
AU2004273779A2 AU2004273779A2 (en) 2005-03-31
AU2004273779B2 true AU2004273779B2 (en) 2009-10-22

Family

ID=34375188

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004273779A Active AU2004273779B2 (en) 2003-06-04 2004-06-03 Compositions for inactivating pathogenic microorganisms, methods of making the compositions, and methods of use thereof

Country Status (4)

Country Link
EP (1) EP1633322A2 (fr)
AU (1) AU2004273779B2 (fr)
CA (1) CA2528095C (fr)
WO (1) WO2005027872A2 (fr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7763663B2 (en) 2001-12-19 2010-07-27 University Of Massachusetts Polysaccharide-containing block copolymer particles and uses thereof
US8067371B2 (en) 2003-05-09 2011-11-29 The Trustees Of Columbia University In The City Of New York RAGE G82S-related methods and compositions for treating inflammatory disorders
US20080274195A1 (en) 2005-07-18 2008-11-06 University Of Massachusetts Lowell Compositions and Methods for Making and Using Nanoemulsions
AU2016244292A1 (en) * 2005-07-18 2016-11-03 University Of Massachusetts Lowell Compositions and methods for making and using nanoemulsions
WO2008051186A2 (fr) 2005-08-09 2008-05-02 Nanobio Corporation Compositions de nano-émulsion ayant une activité anti-inflammatoire
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
PT3144013T (pt) 2005-12-01 2019-02-07 Univ Massachusetts Lowell Nanoemulsões botulínicas
EP2010149A1 (fr) * 2006-04-07 2009-01-07 Novavax, Inc. Compositions nanostructures aux proprietes antibacteriennes, antifongiques, anti-levures et/ou antivirales
EP2012771A4 (fr) * 2006-04-13 2010-01-27 Univ Michigan Vaccins à base d'une nanoémulsion
US9839685B2 (en) 2006-04-13 2017-12-12 The Regents Of The University Of Michigan Methods of inducing human immunodeficiency virus-specific immune responses in a host comprising nasally administering compositions comprising a naonemulsion and recombinant GP120 immunogen
US10138279B2 (en) 2006-04-13 2018-11-27 Regents Of The University Of Michigan Compositions and methods for Bacillus anthracis vaccination
FR2907012B1 (fr) 2006-10-12 2012-09-21 Galderma Sa Composition dermatologique comprenant des nanocapsules d'avermectine, son procede de preparation et son utilisation
US20100150994A1 (en) 2006-12-01 2010-06-17 Anterios, Inc. Amphiphilic entity nanoparticles
CA2671133C (fr) 2006-12-01 2015-11-24 Anterios, Inc. Nanoparticules peptidiques et utilisations de celles-ci
EP1938801A1 (fr) 2006-12-22 2008-07-02 Biofrontera Bioscience GmbH Nanoémulsion
DE102007007698A1 (de) * 2007-02-09 2008-08-21 Exner, Heinrich, Dr. Verwendung einer hochemulgierten Silikonöl-Emulsion (HSE)zur Herstellung eines Medikamentes
CN101765423B (zh) 2007-05-31 2014-08-06 安特里奥公司 核酸纳米粒子和其用途
BRPI0705564B8 (pt) * 2007-10-10 2021-05-25 Embrapa Pesquisa Agropecuaria sistema do tipo cristal líquido contínuo contendo co-solvente portador de substâncias fracamente solúveis em água, seu processo de obtenção e seus usos
EP2278997B1 (fr) 2008-04-21 2016-08-10 Nanobio Corporation Vaccin antigrippal à base de nanoémulsion
US8226965B2 (en) 2008-04-25 2012-07-24 Nanobio Corporation Methods of treating fungal, yeast and mold infections
US20090269394A1 (en) * 2008-04-25 2009-10-29 Nanobio Corporation Methods and compositions for treating onchomycosis
US8877208B2 (en) 2008-05-23 2014-11-04 The Regents Of The University Of Michigan Multivalent nanoemulsion vaccines
WO2009158687A1 (fr) 2008-06-26 2009-12-30 Anterios, Inc. Administration dermique
US20100092526A1 (en) 2008-09-26 2010-04-15 Nanobio Corporation Nanoemulsion therapeutic compositions and methods of using the same
WO2010076812A1 (fr) * 2008-12-31 2010-07-08 Sunev Pharma Solution Limited Nouvelles formules phytosanitaires topiques pour le traitement de l'acné et des troubles cutanés
RU2011154128A (ru) * 2009-06-05 2013-07-20 Сунев Фарма Солюшн Лимитед Микроэмульсии для местного применения для лечения ревматических расстройств
AU2013213678B2 (en) * 2009-12-03 2016-06-23 Novartis Ag Arranging interaction and back pressure chambers for microfluidization
EP2601933B1 (fr) 2009-12-03 2015-10-07 Novartis AG Filtration hydrophile pendant la fabrication d'adjuvants de vaccins
CL2012001399A1 (es) 2009-12-03 2013-03-08 Novartis Ag Metodo para fabricar adyuvante para vacuna (emulsion aceite/agua con escualeno, polisorbato 80 y trioleato de sorbitan), que comprende (i) formar primera emulsion en homogenizador desde un contendor a otro para formar segunda emulsion, (ii) y microfluidizar primera emulsion para formar segunda emulsion.
DE102009056884B4 (de) 2009-12-03 2021-03-18 Novartis Ag Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
DE102009056883B4 (de) 2009-12-03 2012-08-16 Novartis Ag Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
RS52565B (en) † 2009-12-03 2013-04-30 Novartis Ag METHOD OF INTERACTION AND REVERSE PRESSURE FOR MICROFLUIDIZATION
EP2638895B1 (fr) 2009-12-03 2024-03-20 Seqirus UK Limited Circulation de composants pendant l'homogénéisation des émulsions
DE102009056871A1 (de) 2009-12-03 2011-06-22 Novartis AG, 4056 Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
DE202010004750U1 (de) * 2010-04-09 2011-10-11 Biofrontera Bioscience Gmbh Pharmazeutische oder/und kosmetische Zusammensetzung zur Behandlung der Haut
US9597385B2 (en) 2012-04-23 2017-03-21 Allertein Therapeutics, Llc Nanoparticles for treatment of allergy
WO2014206857A1 (fr) * 2013-06-28 2014-12-31 Universitat Autonoma De Barcelona Formulations huile-dans-l'eau de mycobacterium et utilisations associées
WO2015143444A1 (fr) * 2014-03-21 2015-09-24 University Of Florida Research Foundation, Inc. Utilisation d'aldéhydes formulés avec des nanoparticules et/ou des nanoémulsions pour augmenter la résistance aux maladies de plantes vis-à-vis des liberibacters
CN104274405A (zh) * 2014-10-21 2015-01-14 河南牧翔动物药业有限公司 一种水包油型复方头孢噻呋纳米乳抗菌药物
EP3253372B8 (fr) * 2015-02-06 2022-06-22 Woodstock Sterile Solutions, Inc. Préparation d'une émulsion huile dans l'eau pour formulations pharmaceutiques stabilisées par un polymère
AU2017315679B2 (en) 2016-08-23 2023-12-14 Akouos, Inc. Compositions and methods for treating non-age-associated hearing impairment in a human subject
BR112019010131A2 (pt) 2016-11-21 2019-10-08 Eirion Therapeutics Inc entrega transdérmica de agentes grandes
CN106924730B (zh) * 2017-02-14 2019-11-08 商丘美兰生物工程有限公司 猪伪狂犬病毒芦荟胶纳米乳佐剂灭活苗及其制备方法
US11266580B2 (en) 2018-01-23 2022-03-08 Conopco, Inc. Transparent nanoemulsions comprising lauric oil
WO2019145248A1 (fr) 2018-01-23 2019-08-01 Unilever Plc Procédé de fabrication de nanoémulsions transparentes comprenant de l'huile laurique
IL295747A (en) 2020-02-21 2022-10-01 Akouos Inc Preparations and methods for the treatment of hearing impairment that is not related to age in humans
CN113662006B (zh) * 2021-06-30 2022-05-20 南京凯创协同纳米技术有限公司 一种可杀灭细菌灭活病毒的微纳锌的制备方法
WO2024005601A1 (fr) * 2022-06-30 2024-01-04 씨제이제일제당(주) Composition médicale

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2912426B2 (ja) * 1990-06-15 1999-06-28 鐘紡株式会社 微細化エマルション組成物
US6506803B1 (en) * 1999-04-28 2003-01-14 Regents Of The University Of Michigan Methods of preventing and treating microbial infections
ES2291379T3 (es) * 2000-12-27 2008-03-01 Ares Trading S.A. Nanoparticulas lipidicas anfifilicas para la incorporacion de peptidos y/o proteinas.
JP2006512401A (ja) * 2001-06-05 2006-04-13 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン ナノエマルジョンワクチン

Also Published As

Publication number Publication date
CA2528095C (fr) 2014-10-14
AU2004273779A1 (en) 2005-03-31
EP1633322A2 (fr) 2006-03-15
CA2528095A1 (fr) 2005-03-31
WO2005027872A3 (fr) 2006-03-09
AU2004273779A2 (en) 2005-03-31
WO2005027872A2 (fr) 2005-03-31

Similar Documents

Publication Publication Date Title
AU2004273779B2 (en) Compositions for inactivating pathogenic microorganisms, methods of making the compositions, and methods of use thereof
US9131680B2 (en) Compositions for inactivating pathogenic microorganisms, methods of making the compositions, and methods of use thereof
CA2618974C (fr) Compositions de nanoemulsions possedant une activite anti-inflammatoire
CA2395678C (fr) Compositions antimicrobiennes et procedes d'utilisation
US7767216B2 (en) Antimicrobial compositions and methods of use
AU2002350587B2 (en) Antimicrobial nanoemulsion compositions and methods
US8771731B2 (en) Antimicrobial nanoemulsion compositions and methods
US8236335B2 (en) Antimicrobial nanoemulsion compositions and methods
US20020045667A1 (en) Non-toxic antimicrobial compositions and methods of use
WO2005030172A1 (fr) Compositions antimicrobiennes en nanoemulsion et methodes associees
JP2010209109A (ja) 抗微生物ナノエマルジョンの組成物および方法

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 05 MAY 2006

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE PRIORITY DETAILS FROM 60/457,633 04 JUN 2003 US TO 60/475,633 04 JUN 2003 US

FGA Letters patent sealed or granted (standard patent)